Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 20/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL16568602 | 0.99 | FGFR1 (0.81) | FGFR1 | |
| SCHEMBL15045699 | 0.90 | FGFR1 (0.82) | FGFR1 | |
| SCHEMBL15019898 | 0.90 | FGFR1 (0.84) | FGFR1 | |
| SCHEMBL15022966 | 0.90 | FGFR1 (1.00) | FGFR1 | |
| SCHEMBL17509986 | 0.90 | FGFR1 (0.82) | FGFR1 | |
| Hydrochloric Acid SCHEMBL17509989 | 0.89 | FGFR1 (0.81) | FGFR1 | |
| SCHEMBL15018897 | 0.88 | FGFR1 (1.00) | FGFR1 | |
| SCHEMBL15045639 | 0.86 | FGFR1 (1.00) | FGFR1 | |
| SCHEMBL15045734 | 0.86 | FGFR1 (1.00) | FGFR1 | |
| SCHEMBL15045722 | 0.86 | FGFR1 (1.00) | FGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9598416-B2 | Substituted benzothienyl-pyrrolotriazines and uses thereof in the treatment cancer | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2017-03-21 | — | — | US | disclosed |
| US-9598416-B2 | Substituted benzothienyl-pyrrolotriazines and uses thereof in the treatment cancer | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2017-03-21 | — | — | US | disclosed |
| EP-2791143-B1 | SUBSTITUTED BENZOTHIENYL-PYRROLOTRIAZINES AND USES THEREOF IN THE TREATMENT OF CANCER | BAYER IP GMBH (DE) | 2016-02-24 | — | — | EP | disclosed |
| US-20150080371-A1 | SUBSTITUTED BENZOTHIENYL - PYRROLOTRIAZINES AND USES THEREOF IN THE TREATMENT CANCER | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-03-19 | — | — | US | disclosed |
| US-20150080371-A1 | SUBSTITUTED BENZOTHIENYL - PYRROLOTRIAZINES AND USES THEREOF IN THE TREATMENT CANCER | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-03-19 | — | — | US | disclosed |
| WO-2013087647-A1 | SUBSTITUTED BENZOTHIENYL - PYRROLOTRIAZINES AND USES THEREOF IN THE TREATMENT CANCER | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150080371-A1 | SUBSTITUTED BENZOTHIENYL - PYRROLOTRIAZINES AND USES THEREOF IN THE TREATMENT CANCER | STK25, JAK2, JAK1 | FGFR1 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.